Physician

John Michael Nicklas, MD

According to 2025 Medicare claims, John Nicklas, MD (NPI: 1801972864) practices advanced heart failure and transplant cardiology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1891205969; TIN: 386006309) and primary practice location at 48109-5000. Nicklas is affiliated with the POM ACO (ACO ID: A1297) and Mosaic ACO (ACO ID: A5033), participating under the MSSP model.

Nicklas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 148 traditional Medicare patients, billed 432 HCPCS/CPT codes, and received $45,019 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 2,527 prescription claims across 224 beneficiaries totaling $1,105,252 in drug costs, led by Vyndaqel (Tafamidis Meglumine). DME data shows 281 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $70,440 to $45,019. In contrast, Part D prescription costs have moved sharply higher in recent years, from $271,604 to $1,105,252. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $27,462 to $11,147.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	238	1,073	$70,440
2016	258	1,013	$74,154
2017	209	817	$54,857
2018	1,154	2,097	$86,002
2019	269	976	$72,742
2020	238	744	$61,165
2021	218	584	$56,232
2022	217	612	$58,052
2023	192	401	$39,811
2024	148	432	$45,019

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	137	1,904	$271,604
2016	134	1,880	$213,437
2017	126	1,668	$160,867
2018	160	1,796	$150,533
2019	176	2,073	$214,349
2020	200	2,343	$368,790
2021	222	2,341	$498,634
2022	221	2,513	$630,609
2023	228	2,452	$698,701
2024	224	2,527	$1,105,252

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	62	680	$128,124
2016	67	736	$260,506
2017	40	598	$64,479
2018	40	678	$45,682
2019	48	560	$34,276
2020	38	481	$38,596
2021	N/R	337	$28,899
2022	N/R	291	$25,461
2023	N/R	179	$21,024
2024	N/R	281	$18,724

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	15	63	$172
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	24	25	$129
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	60	86	$102
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	39	167	$95
99239	Hospital discharge day management, more than 30 minutes	15	15	$91

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndaqel	Tafamidis Meglumine	16	480	$348,213
Vyndamax	Tafamidis	11	330	$232,459
Entresto	Sacubitril/Valsartan	118	7,147	$151,103
Eliquis	Apixaban	126	7,063	$131,125
Jardiance	Empagliflozin	79	4,950	$92,025

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	51	$7,436
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	22	$5,688
J2260	Injection, milrinone lactate, 5 mg	N	N/R	50	$2,432
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	50	$1,017
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	31	$677

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for John Michael Nicklas, MD?

Tedicare shows public-source Medicare data for John Michael Nicklas, MD (NPI 1801972864), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Michael Nicklas, MD have ACO affiliation data?

John Michael Nicklas, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Mosaic ACO (MSSP, ACO ID A5033).

What billing organization is linked to John Michael Nicklas, MD?

John Michael Nicklas, MD is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1891205969) in the available physician profile data.

Does John Michael Nicklas, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.